Cynata Therapeutics Limited has released a press release.
Encouraging Early Data-Cynata Clinical Trial Proceeds
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Final Preclinical Asthma Study Confirms Efficacy
- United States Patent Allowance for Core Cynata Technology
- Enrolment Completed in 1st Cohort of Cynata Clinical Trial
- September 2017 Quarterly Report
- Notice of Annual General Meeting/Proxy Form
Later from Cynata Therapeutics
- Cyanta & Celularity Inc Execute MOU
- Cynata Treats First Patient in Cohort B
- December 2017 Quarterly Report
- Cynata Engineered MSC Study Review Reveals Promising Results
- Excellent Data from Final Preliminary Evaluation Period
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics